Development of highly potent protease‐activated receptor 2 agonists via synthetic lipid tethering

• Published in: The FASEB journal Vol. 27; no. 4; pp. 1498 - 1510
• Main Authors: Flynn, Andrea N., Hoffman, Justin, Tillu, Dipti V., Sherwood, Cara L., Zhang, Zhenyu, Patek, Renata, Asiedu, Marina N. K., Vagner, Josef, Price, Theodore J., Boitano, Scott
• Format: Journal Article
• Language: English
• Published: Bethesda, MD, USA Federation of American Societies for Experimental Biology 01-04-2013
• Subjects: Ca2+ signaling; Calcium - metabolism; Calcium Signaling - drug effects; Cell Line - drug effects; Humans; Hyperalgesia - drug therapy; Ligands; Lipid Metabolism - drug effects; MAPK; Ornithine - analogs & derivatives; Ornithine - pharmacology; Palmitates - pharmacology; PAR2, G‐protein coupled receptor; Peptidomimetics - pharmacology; Receptor, PAR-2 - agonists; Research Communications; Structure-Activity Relationship; xCELLigence RTCA
• ISSN: 0892-6638; 1530-6860
• DOI: 10.1096/fj.12-217323

Protease‐activated receptor‐2 (PAR2) is a G‐protein coupled receptor (GPCR) associated with a variety of pathologies. However, the therapeutic potential of PAR2 is limited by a lack of potent and specific ligands. Following proteolytic cleavage, PAR2 is activated through a tethered ligand. Hence, we reasoned that lipidation of peptidomimetic ligands could promote membrane targeting and thus significantly improve potency and constructed a series of synthetic tethered ligands (STLs). STLs contained a peptidomimetic PAR2 agonist (2‐aminothiazol‐4‐yl‐LIGRL‐NH2) bound to a palmitoyl group (Pam) via polyethylene glycol (PEG) linkers. In a high‐throughput physiological assay, these STL agonists displayed EC50 values as low as 1.47 nM, representing a ~200 fold improvement over the untethered parent ligand. Similarly, these STL agonists were potent activators of signaling pathways associated with PAR2: EC50 for Ca2+ response as low as 3.95 nM; EC50 for MAPK response as low as 9.49 nM. Moreover, STLs demonstrated significant improvement in potency in vivo, evoking mechanical allodynia with an EC50 of 14.4 pmol. STLs failed to elicit responses in PAR2 cells at agonist concentrations of >300‐fold their EC50 values. Our results demonstrate that the STL approach is a powerful tool for increasing ligand potency at PAR2 and represent opportunities for drug development at other protease activated receptors and across GPCRs.—Flynn, A. N., Hoffman, J., Tillu, D. V., Sherwood, C. L., Zhang, Z., Patek, R., Asiedu, M. N. K., Vagner, J., Price, T. J., Boitano, S. Development of highly potent protease‐activated receptor 2 agonists via synthetic lipid tethering. FASEB J. 27, 1498–1510 (2013). www.fasebj.org